` ATE (Antibe Therapeutics Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

ATE
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, ATE has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +21% growth.

Stocks Performance
ATE vs S&P TSX Composite Index (Canada)

Loading
ATE
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
ATE vs S&P TSX Composite Index (Canada)

Loading
ATE
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
ATE vs S&P TSX Composite Index (Canada)

Loading
ATE
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Antibe Therapeutics Inc vs Peers

S&P TSX Composite Index (Canada)
ATE
LLY
JNJ
ROG
NOVO B
Add Stock

Antibe Therapeutics Inc
Glance View

Market Cap
4.7m CAD
Industry
Pharmaceuticals

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The company is headquartered in Toronto, Ontario and currently employs 37 full-time employees. The company went IPO on 2013-06-18. The firm is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.

ATE Intrinsic Value
Not Available
Back to Top